Hep B question

[Guest guest]

At 09:03 AM 07/27/2000 -0400, you wrote:

>

>

>I was also send this phrase. Does it hold any merit. It is the only thing

>my friend will vaccinate for:

and its the WORST one!

>

>Hepatitis B (the

>only one with an approved vaccination so far) is an untreatable viral liver

>disease. There are simply no medicines with which to treat it.

>

>Diane

http://www.909shot.com/newsletterexcerpts.htm

Excerpts from " Hepatitis B Vaccine - The Untold Story "

THE VACCINE REACTION

" When it happens to you or your child, the risks are 100% "

Published by the National Vaccine Information Center

Barbara Loe Fisher, Editor

Excerpts from " HEPATITIS B VACCINE: THE UNTOLD STORY "

Hepatitis B Not Highly Contagious - Unlike other infectious diseases for

which vaccines have been developed and mandated in the U.S., hepatitis B is

not common in childhood and is not highly contagious. Hepatitis B is

primarily an adult disease transmitted through infected body fluids, most

frequently infected blood, and is prevalent in high risk populations such as

needle using drug addicts; sexually promiscuous heterosexual and homosexual

adults; residents and staff of custodial institutions such as prisons;

health care workers exposed to blood; persons who require repeated blood

transfusions and babies born to infected mothers.

According to CDC Prevention Guidelines: A Guide to Action (1997), a book

written by federal public health officials at the U.S. government Centers

for Disease Control (CDC), " the sources of [hepatitis B] infection for most

cases include intravenous drug use (28%), heterosexual contact with infected

persons or multiple partners (22%) and homosexual activity (9%). " According

to on's Principles of Internal Medicine (1994), mother to child

transmission of hepatitis B " is uncommon in North America and western

Europe. "

Although CDC officials have made statements that hepatitis B is easy to

catch through sharing toothbrushes or razors, Mast, M.D., Chief of the

Surveillance Section, Hepatitis Branch of the CDC, stated in a 1997 public

hearing that: " although [the hepatitis B virus] is present in moderate

concentrations in saliva, it's not transmitted commonly by casual contact. "

Hepatitis B Not A Killer Disease For Most - Symptoms of hepatitis B disease

include nausea, vomiting, fatigue, low grade fever, pain and swelling in

joints, headache and cough that may occur one to two weeks before the onset

of jaundice (yellowing of the skin) and enlargement and tenderness of the

liver, which can last for three to four weeks. Fatigue can last up to a

year. According to on's, in cases of acute hepatitis B " most patients

do not require hospital care " and " 95 percent of patients have a favorable

course and recover completely " with the case-fatality ratio being " very low

(approximately 0.1 percent). "

Those who recover completely from hepatitis B infection acquire life-long

immunity. Of those who do not recover completely, fewer than 5 percent

become chronic carriers of the virus with just one quarter of these in

danger of developing life threatening liver disease later in life, according

to Robbins Pathologic Basis of Disease (1994), a medical college textbook.

The Guide to Clinical Preventive Services (1996), written under the

supervision of the U.S. Department of Health and Human Services (DHHS),

states that the risk of developing a chronic hepatitis B infection is higher

in infected infants than in infected older children and adults: " Infections

during infancy, while estimated to represent only 1-3% of cases, account for

20-30% of chronic infections. " Because infants born to infected mothers are

at highest risk for developing chronic hepatitis B infections, routine

screening of pregnant women for hepatitis B infection is one of the most

important public health measures that can be taken to prevent chronic

hepatitis B carriers. The Merck Manual (1992), a major medical reference

used by physicians, notes that " postexposure vaccination is recommended for

newborn infants of hepatitis B positive mothers. "

Hepatitis B Low In U.S. - The U.S. and western Europe have always had among

the lowest rates of hepatitis B disease in the world (0.1% to 0.5% of the

general population) compared to countries in the Far East and Africa, where

the disease affects 5-20% or more of the population. According to Guide to

Clinical Preventive Services, in the U.S. " the greatest reported incidence

[of hepatitis B] occurs in adults aged 20-39 " and " the number of cases

peaked in 1985 and has shown a continuous gradual decline since that time. "

Even though hepatitis B disease is uncommon in the general population in the

U.S., it continues to be high among those engaged in high-risk behaviors,

especially IV drug use. Guide to Clinical Preventive Services states that

" In recent years, a growing number of injection drug users have become

infected; currently, between 60% and 80% of persons who use illicit drugs

parenterally (through the skin such as with a needle stick) have serologic

evidence of [hepatitis B] infection. "

In 1991, there were 18,003 cases of hepatitis B reported in the U.S. out of

a total U.S. population of 248 million. According to the October 31, 1997

Morbidity and Mortality Weekly Report published by the CDC, in 1996 there

were 10,637 cases of hepatitis B reported in the U.S. with 279 cases

reported in children under the age of 14 and the CDC stated that " Hepatitis

B continues to decline in most states, primarily because of a decrease in

the number of cases among injecting drug users and, to a lesser extent,

among both homosexuals and heterosexuals of both sexes. "

CDC Recommends All Infants Get Hep B Vaccine - Even though hepatitis B is an

adult disease, is not highly contagious, is not deadly for most who contract

it, and is not in epidemic form in the U.S. (except among high risk groups

such as IV drug addicts), in 1991 the Advisory Committee on Immunization

Practices (ACIP) of the Centers for Disease Control (CDC) recommended that

all infants be injected with the first dose of hepatitis B vaccine at birth

before being discharged from the hospital newborn nursery. A similar

recommendation was also made by the Committee on Infectious Diseases of the

American Academy of Pediatrics (AAP). This, despite the fact almost nothing

is known about the health and integrity of an individual baby's immune and

neurological systems at birth.

In 1991, media reports generated by the CDC used hepatitis B disease

statistics that were not anchored in documented fact but are still used

today to promote mass hepatitis B vaccination. Most of the inflated disease

statistics originate with statements generated by the Centers for Disease

Control. In the 1991 ACIP Recommendations calling for mass vaccination with

hepatitis B vaccine published in the Morbidity and Mortality Weekly Report,

the CDC states that there are an " estimated 1 million-1.25 million persons

with chronic hepatitis B infection in the United States " and that " each year

approximately 4,000-5,000 of these persons die from chronic liver disease "

and that " an estimated 200,000-300,000 new [hepatitis B] infections occurred

annually during the period 1980-1991. " The CDC gives no scientific reference

for this data other than the CDC.

Just one year before the government's call for mass vaccination, hepatitis B

vaccine maker Kline Beecham in their 1990 hepatitis B vaccine product

insert stated, " The CDC estimates that there are approximately 0.5 to 1.0

million chronic carriers of hepatitis B virus in the U.S. and that this pool

of carriers grows by 2% to 3% (12,000 to 20,000 individuals) annually. "

Hep B Vaccine Licensed By FDA Without Adequate Proof of Long Term Safety -

In 1986, the FDA gave Merck & Co. a license to market the first recombinant

DNA hepatitis B vaccine, which replaced the old hepatitis B vaccines made

from blood taken from human chronic hepatitis B virus carriers. In awarding

Merck & Co. and, later, Kline Beecham Pharmaceuticals, licenses to

market their genetically engineered hepatitis B vaccines in the U.S., the

FDA allowed both drug companies to use " safety " studies which only included

a few thousand children monitored for only four or five days after

vaccination to check for reactions. As " proof " their hepatitis B vaccine is

safe to be used in children, Merck & Co. stated in their 1993 product insert

that " In a group of studies, 1636 doses of RECOMBIVAX HB were administered

to 653 healthy infants and children (up to 10 years of age) who were

monitored for 5 days after each dose. "

Merck & Co. found that injection site and systemic complaints, such as

fatigue and weakness, fever, headache and arthralgia (joint pain), were

reported following up to 17 percent of all hepatitis B injections. Because

the FDA did not require drug companies to provide scientific evidence that

hepatitis B vaccine does not compromise the immune and neurological systems

of children and adults over weeks, months or years post-vaccination, Merck &

Co. warns in the 1996 product insert that " As with any vaccine, there is the

possibility that broad use of the vaccine could reveal adverse reactions not

observed in clinical trials " and Kline Beecham (1993) has a similar

warning that " it is possible that expanded commercial use of the vaccine

could reveal rare adverse reactions.

Another warning in the Merck 1996 product insert is " it is also not known

whether the vaccine can cause fetal harm when administered to a pregnant

woman or can affect reproduction capacity " and " it is not known whether the

vaccine is excreted in human milk. Because many drugs are secreted in human

milk, caution should be exercised when the vaccine is administered to a

nursing woman. "

And, although doctors routinely inject hepatitis B vaccine into children

along with many other vaccines such as DPT, HIB, MMR and chicken pox

vaccine, Merck & Co. state in the 1996 product insert: " Specific data are

not yet available for the simultaneous administration of RECOMBIVAX HB with

other vaccines. "

Hep B Vaccine Efficacy Also Questioned - All vaccines stimulate only an

artificial, temporary immunity, and the length of immunity conferred by the

hepatitis B vaccine and the future need for more " booster " doses later in

life is still not clear. Merck & Co state in their 1996 hepatitis B vaccine

product insert that " the duration of the protective effect of RECOMBIVAX HB

in healthy vaccinees is unknown at present and the need for booster doses is

not yet defined. "

In the CDC Prevention Guidelines: A Guide to Action (1997), the CDC states

" The duration of protection [of hepatitis B vaccine] and need for booster

doses are not yet fully defined. Between 30% and 50% of persons who develop

adequate antibody after three doses of vaccine will lose detectable antibody

within 7 years but protection against viremic infection and clinical disease

appears to persist. " If immunity only lasts 7 years, babies vaccinated with

hepatitis B vaccine may be candidates for more shots at age seven.

IOM Report Reveals Lack Of Adequate Scientific Studies - In Adverse Events

Associated with Childhood Vaccines published in 1994 by the Institute of

Medicine, National Academy of Sciences, observations about the limitations

of hepatitis B vaccine studies included the statements that " it is important

to note that individual trials usually involved a few hundred subjects for

study...when larger vaccination programs were monitored, observations of

adverse events were necessarily less detailed and less accurately reported "

and " the studies were not designed to assess serious, rare adverse events;

the total number of recipients is too small and the follow-up generally too

short to detect rare or delayed serious adverse reactions. "

The IOM report also noted that no controlled observational studies or

controlled clinical trials have ever been held to evaluate repeated reports

that hepatitis B vaccine can cause Guillain-Barre syndrome; arthritis;

transverse myelitis, optic neuritis, multiple sclerosis and other central

demyelinating diseases of the nervous system (degeneration of the myelin

sheath of the brain that helps transmit nerve impulses); or sudden infant

death syndrome (SIDS).

A major conclusion of the Institute of Medicine report was that almost no

basic science research has been undertaken to define at the cellular and

molecular level the biological mechanism of vaccine-induced injury and

death. The report concluded that " The lack of adequate data regarding many

of the adverse events under study was of major concern to the

committee...the committee encountered many gaps and limitations in knowledge

bearing directly or indirectly on the safety of vaccines. These include

inadequate understanding of the biologic mechanisms underlying adverse

events following natural infection or immunization, insufficient or

inconsistent information from case reports and case series...and inadequate

size or length of follow-up of many population-based epidemiologic

studies…. "

Medical Literature Cites Immune System/Brain Damage - During the past

decade, there have been many reports in the medical literature (primarily in

international medical journals rather than U.S. medical journals) that

hepatitis B vaccination is causing chronic immune and neurological disease

in children and adults, including lupus: Tudela & Bonal (1992); Mamoux &

Dumont (1994); Guiserix (1996); arthritis, including polyarthritis and

rheumatoid arthritis: Christan & Helin (1987); Hachulla et al (1990);

on & Nye (1990); Biasi et al (1993),(1994); Vautier & Carty (1994);

Hassan & Oldham (1994); Rheumatic Review (1994); Gross et al (1995); Pope et

al (1995); Cathebras et al (1996); Soubrier et al (1997); Guillain Barre

Syndrome GBS): Shaw et al (1988), Tuohy (1989); demyelinating disorders such

as optic neuritis, Bell's Palsy, demyelinating neuropathy, transverse

myelitis and multiple sclerosis: Shaw et al (1988); WHO (1990); Reutens et

al (1990); Herroelen et al (1991); Nadler (1993); Brezin et al (1993);

Mahassin et al (1993); Kaplanski et al (1995); Baglivo et al (1996);

Marsaudon & Barrault (1996); Berkman et al (1996); Waisbren (1997); diabetes

mellitus: Poutasi (1996); Classen (1996); chronic fatigue: Salit (1993);

Delage et al (1993); vascular disorders: Fried et al (1987); Goolsby (1989);

Cockwell et al (1990); Poullin & (1994); Mathieu et al (1996);

Graniel et al (1997); and others.

In 1996, Burton A. Waisbren, M.D., a cell biologist and infectious disease

specialist, who is a founding member of the Infectious Disease Society of

America and past President of the Infectious Disease Society of Milwaukee,

pointed out in the Wisconsin Medical Journal that " there is an increasing

number of reports in the refereed medical literature about demyelinizing

diseases occurring after an individual has received the hepatitis B

vaccination...since the hepatitis B virus itself has been reported to cause

autoimmune problems, should we not be wary of giving antigens that seem to

have triggered these problems? " Waisbren, in a presentation before a 1996

Institute of Medicine Vaccine Safety Forum, warned that genetically

engineered hepatitis B vaccines contain polypeptide sequences that are

present in human neurologic tissues such as myelin and that, by a mechanism

called molecular mimicry, these polypeptides can act as autoantigens which

can induce autoimmune demyelinating diseases of the brain such as multiple

sclerosis.

In that same year, Montinari et al published a study in Italy evaluating 30

children and adults, the majority aged 3 to 9 months, who suffered central

nervous system disorders, such as seizures and autism, following hepatitis B

vaccination. The purpose of the study was to investigate whether there is an

immunogenetic basis (autoimmune type) responsible for the demyelination

process in the brain that can occur following recombinant hepatitis B

vaccination. The authors concluded " autoimmune diseases are more frequent in

nations where vaccines are widely used, the so called " clear " communities "

and they identified several potential genetic markers that " may visualize

risk patients for autoimmune diseases following hepatitis B vaccination.

Montinari's work to identify genetic factors for predisposition to hepatitis

B vaccine reactions is important in light of the study in 1989 by Alper et

al to identify genetic factors for those who do not respond to hepatitis B

vaccination. In that study, the authors concluded that there was genetic

predisposition to failure to respond to the vaccine. They stated: " These

results support our hypothesis that the production of anti-HBsAg

[vaccine-induced antibodies] is a dominant trait and that the inability to

produce high titers of anti-HBsAG after adequate immunization is a recessive

trait... " The authors concluded that the genetic markers they identified are

most prevalent in caucasians of European descent " and is associated with a

wide variety of diseases with autoimmune features in this population,

including Type 1 diabetes mellitus... "

In 1996, Barthelow Classen, M.D., CEO of Classen Immunotherapies Inc.,

published an epidemiologic study in the New Zealand Medical Journal and

reported that there was a 60 percent increase in Type 1 diabetes (juvenile

diabetes) following a massive campaign in New Zealand from 1988 to 1991 to

vaccinate babies six weeks of age or older with hepatitis B vaccine. His

analysis of a group of 100,000 New Zealand children prospectively followed

since 1982 showed that the incidence of diabetes before the hepatitis B

vaccination program began in 1988 was 11.2 cases per 100,000 children per

year while the incidence of diabetes following the hepatitis B vaccination

campaign was 18.2 cases per 100,000 children per year.

[image] NVIC Home

©Copyright 1996-98 National Vaccine Information Center

512 W. Maple Ave., Suite 206, Vienna, VA 22180

(703) 938-DPT3 FAX: 938-5768

1-800-909-SHOT

email: info@...

----------------------------------------------------------------------------

--------------------------------------------------------

Sheri Nakken, R.N., MA

Vaccination Information & Choice Network, Nevada City CA

http://www.nccn.net/~wwithin/vaccine.htm

ANY INFO OBTAINED HERE NOT TO BE CONSTRUED AS MEDICAL OR LEGAL ADVICE. THE

DECISION TO VACCINATE IS YOURS AND YOURS ALONE.

Well Within's Earth Mysteries & Sacred Site Tours

http://www.nccn.net/~wwithin

International Tours, Homestudy Courses, ANTHRAX & OTHER Vaccine Dangers

Education, Homeopathic Education

KVMR Broadcaster/Programmer/Investigative Reporter, Nevada City CA

CEU's for nurses, Books & Multi-Pure Water Filters

[Guest guest]

" Viral hepatitis of all types is one of the easiest diseases for ascorbic

acid to cure. " ---Dr Cathcart, M.D.

http://www.seanet.com/~alexs/ascorbate/

Hep B Question

>

>

> I was also send this phrase. Does it hold any merit. It is the only

thing

> my friend will vaccinate for:

>

> Hepatitis B (the

> only one with an approved vaccination so far) is an untreatable viral

liver

> disease. There are simply no medicines with which to treat it.

>

> Diane

>

>

>

>

>

>

>

>

>

[Guest guest]

I was reading that statement by Barbara Fisher( ithink) and it sums up

exactly why i chose not to vaccinate. It may be 1 in however many thousands

that suffer from a " severe " reaction, but i have only one Zakharia and one

Elia. When i explained this to a few peds, all i got back was blank stares.

Even one reaction is one too many!!!

Christin

[Guest guest]

At 04:36 PM 07/28/2000 EDT, you wrote:

>I was reading that statement by Barbara Fisher( ithink) and it sums up

>exactly why i chose not to vaccinate. It may be 1 in however many thousands

>that suffer from a " severe " reaction, but i have only one Zakharia and one

>Elia. When i explained this to a few peds, all i got back was blank

stares.

>Even one reaction is one too many!!!

>Christin

Read Mendelsohn's Confession of a Medical Heretic and you'll see why they

give you blank stares.

Disgusting!

Sheri

--------------------------------------------------------

Sheri Nakken, R.N., MA

Vaccination Information & Choice Network, Nevada City CA

http://www.nccn.net/~wwithin/vaccine.htm

ANY INFO OBTAINED HERE NOT TO BE CONSTRUED AS MEDICAL OR LEGAL ADVICE. THE

DECISION TO VACCINATE IS YOURS AND YOURS ALONE.

Well Within's Earth Mysteries & Sacred Site Tours

http://www.nccn.net/~wwithin

International Tours, Homestudy Courses, ANTHRAX & OTHER Vaccine Dangers

Education, Homeopathic Education

KVMR Broadcaster/Programmer/Investigative Reporter, Nevada City CA

CEU's for nurses, Books & Multi-Pure Water Filters

[Guest guest]

Has anyone done really intensive research on the Hep B vaccine? I'd love to get

some good references on it.I have a question, here's something I pulled from an

article written in JAMA.. " Public health professionals counter by saying that up

to 40% of hepatitis B infections come from unknown sources and that children

under age 5, although a small minority of those with hepatitis B, have the

greatest chance of getting chronic hepatitis B and becoming at high risk of

death from cirrhosis and liver cancer. " JAMA, The Journal of the American

Medical Association, July 7, 1999 v282 i1 p15 Debate Revived on Hepatitis B

Vaccine Value. (Medical News & Perspectives) Marwick; Mike Mitka. I've

seen this statistic before and what I want to know is HOW these children are

getting Hepatitis B? Does anyone know if these is even traceable?Thanks,

a, Aspiring Doula

Mom to Dryden (July 17, 1997)and Niall (April 28, 2001)

Wife to Randy (March 17, 2000)

Learning to cloth diaper, totally breastfeeding, family bedding, researching

vaccines Pacific Northwest mama.

---------------------------------

[Guest guest]

France does not exist as far as the US is concerned.

Nothing outside the US means anything anyway to them.

They know no one can sue here, so why should they care?

Sheri

At 02:43 AM 4/14/2008, you wrote:

I'm astounded ('tho I probably

shouldn't be) that there's no

discussion of changing this practice now that hep b vax manufacturers

are charged with manslaughter in France for not disclosing the

dangers, plus numerous civil cases. France ceased its universal hep b

vax program after so many citizens became seriously ill with a variety

of conditions, including MS.

>

> Not too cynical at all. I was told this explicitly by hospital

staff when I asked this question after my last birth eight years ago.

Mom's Hep B status is irrelevant unless she is planning on sharing a

needle or having sex with her newborn. I refused the shot (it wasn't

being offered in the years I had my first two) and in response to the

quizzical look from the nurse said, " if he picks anyone up on the

way

home, I'll be sure he uses a condom. "

>

> Jake Marcus, J.D.